Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbe3e711dfc7e98da3626934fabb84d2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55527 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0637 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
filingDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baa5f46ba900f79014bc85390aaa3b60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12baa30db074f5fee29cb554d505182f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bbc13448ce04597486ca201c038e592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_041e992505227c2989388f5c70e093f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5691276795314dfbf87f72f567460f3 |
publicationDate |
2018-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3402512-A1 |
titleOfInvention |
Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same |
abstract |
The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the Vα and Vβ polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor. |
priorityDate |
2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |